Genetic Testing – Next generation Sequencing

Reliable Testing – Detects Up to 99% of Variants

We provide targeted DNA sequencing allowing us to focus specific areas of interest at a reduced price and faster delivery time. Our laboratory’s technology can accommodate small blood sample sizes, making it viable alternative to a trip to the phlebotomist and reducing the impact of blood-drawing on patients’ health. ALL GENETIC TESTING REQUIRES A MEDICAL PROVIDER’S OR GENETIC COUNSELOR’S ORDER.

NEXT GENERATION SEQUENCING – GERMLINE MUTATIONS

CYSTIC FIBROSIS

Genetic Testing - Cystic Fibrosis

HEREDITARY CANCER

Genetic Testing - Hereditary Cancer

HEART DISEASE

Genetic Testing - Heart Disease

COAGULATION

Genetic Testing - Coagulation

OBESITY

Genetic Testing - Obesity
Our Obesity Amplicon Sequencing Panel targets 35 genes that were expertly selected based on their association with obesity.  This assay is performed using genomic DNA isolated from human peripheral whole blood specimens.

The test is intended to identify the variants that are associated with obesity. It is performed as a pre-symptomatic genetic test in order to determine whether persons with a family history of obesity, but no current symptoms, has the gene alterations associated with the disease. The test can also be used for post-symptomatic genetic testing to confirm variants of association to obesity.

There is a direct correlation between increasing obesity and higher risk of health problems such as type 2 diabetes, coronary heart disease, hypertension, arthritis and even cancer.  Unraveling the genetic background associated obesity may lead to more efficient ways to manage the obesity phenomenon and diseases associated with it.

AUTOIMMUNE

Genetic Testing - Autoimmune
Our Autoimmune Amplicon Sequencing Panel targets 70 genes associated with autoimmune disease such as systemic lupus, rheumatoid arthritis, juvenile idiopathic arthritis, systemic scleroderma and idiopathic inflammatory myopathy. This assay is performed using genomic DNA isolated from human peripheral whole blood specimens.

The test is intended to identify the variants that are associated with autoimmune disorders. It is performed as a pre-symptomatic genetic test in order to determine whether persons with a family history of a autoimmune disorders, but no current symptoms, have gene alterations associated with the disease. The test can also be used for post-symptomatic genetic testing to confirm variants of association to autoimmune disorders.

AUTISM

Genetic Testing - Immune
Our Autism Amplicon Sequencing Panel assists in the investigation of genomic features associated with autism through sequencing 98 developmental delay genes linked specifically with autism. This assay is performed using genomic DNA isolated from human peripheral whole blood specimens.

The test is intended to identify variants that are associated with autism. The test is performed as a pre-symptomatic genetic testing to evaluate if individuals have the gene alterations associated with the autism. The test can also be used for post-symptomatic genetic testing to confirm variants of association to autism.

Autism is a broad-spectrum disorder. Recent studies have identified that epigenetic factors have an important role in the development of autism. A negative genetic test does not confirm the misdiagnosis of the affected individual.

NEUROMUSCULAR

Genetic Testing - Neuromuscular
Our Neuromuscular Amplicon Sequencing Panel targets 144 genes associated with neuromuscular disease. The test is grouped into three subclasses of neuromuscular disorders: 1) movement disorders, 2) motor neuron disorders and 3) neuromuscular disorders. This assay is performed using genomic DNA isolated from human peripheral whole blood specimens.

The test is intended to identify the variants that are associated with neuromuscular disorders. The test is intended as a pre-symptomatic genetic test to determine whether an individual with a family history of a neuromuscular disease, but no current symptoms, has the gene alterations associated with the disease. The test can also be used for post-symptomatic genetic testing to confirm variants of association to neuromuscular disorders.

NEUROLOGY

Genetic Testing Neurologic
Our Neurology Amplicon Sequencing Panel targets 65 genes associated with the following neurologic disorders: neurodevelopmental disorders, peripheral neuropathy, dementia, cerebrovascular disease and migraine. This assay is performed using genomic DNA isolated from human peripheral whole blood specimens.

The test is intended to identify the variants that are associated with neurodevelopmental disorders. The test is performed as a pre-symptomatic genetic test in order to determine whether an individual with a family history of a neurologic disease, but no current symptoms, has the gene alterations associated with the disease. The test can also be used for post-symptomatic genetic testing to confirm variants of association to neurodevelopmental disorders.

MYOPATHY

Genetic Testing - Myopathy
Our mtDNA Amplicon Sequencing Panel targets 21 mitochondrial genes associated with myopathy that include muscle weakness and wasting and other problems with movement. This assay is performed using mitochondrial DNA isolated from human peripheral mononuclear cells.

The test is intended to identify the variants found in mitochondrial genes that are associated with myopathy. The test is performed as a pre-symptomatic genetic test in order to determine whether an individual with a family history of a myopathy disease, but no current symptoms, has the gene alterations associated with the disease. The test can also be used for post-symptomatic genetic testing to confirm variants of association to myopathy disorders.

EPILEPSY

Genetic Testing - Epilepsy
Our Epilepsy Amplicon Sequencing Panel targets 141 genes associated with the epilepsy syndrome. This assay is performed using genomic DNA isolated from human peripheral whole blood specimens.

The test is intended to identify the variants that are associated with epileptic disorders. The test is performed as a pre-symptomatic genetic test in order to determine whether an individual with a family history of a epilepsy, but no current symptoms, has the gene alterations associated with the disorder. The test can also be used for post-symptomatic genetic testing to confirm variants of association to epileptic disorders.

NUTRITIONAL

Genetic Testing - Nutritional
Our Nutritional Well Being Amplicon Sequencing Panel targets 279 variants in 99 genes associated with gut health challenges that are caused by inflammation, dysbiosis, digestive disturbances and others. It also targets variants that support the production of acetyl CoA, detoxification capacity, folate production, methionine cycle, neurotransmitter production, vitamin D production, exercise and fitness, and others.

The test is intended for the person who is interested in their health and overall well being. This assay is performed using genomic DNA isolated from human peripheral whole blood specimens.

NEXT GENERATION SEQUENCING – SOMATIC MUTATIONS

SOLID TUMOR

Genetic Testing - Solid Tumor

All tests are performed in Ayass BioScience, LLC. Ayass BioScience, LLC (DBA Ayass Lung Clinic, PLLC) is a CLIA certified laboratory. If you have any questions about Genetic Testing Next Generation Sequencing at Ayass BioScience, LLC, please call today at 972-668-6005 or fill out our contact form on the bottom of this page. We will answer any question you might have.